They come out with this kind of news when there is such a precipitous decline in the SPP. Can't make these guys out.
They keep pumping studies in prestigious scientific journals about apabetalon's dual mechanism of action but mention nothing of benefit from the Open-label Phase 2, COVID-19 clinical trial if there is any. They even pump up Eversana and their commercialization capability per se, concerning COVID-19 but decided to conclude its Phase 2 trial in hospitalized COVID-19 patients early, kicking the can down the road once more and decided to focus its resources on the advanced Phase 3 CORAL program. No mention of BOM2. No mention of funding. They got us coming and going.
This is not the kind of news we waited for before the AGM.
jmo
G1945V